1344 GMT - Novo Nordisk sees flat U.S. weekly prescription rate growth for its obesity treatment Wegovy due to competition from U.S. rival Eli Lilly and compounding pharmacies, coupled with reimbursement challenges, Morgan Stanley analysts say. The Danish pharmaceutical company could trim its sales guidance, possibly alongside its 1Q results, due to the slower U.S. prescription growth, they say. While long-term forecasts still indicate potential upside, the future of the obesity market, peak sales potential and longevity of Novo Nordisk's weight loss drug portfolio remain uncertain, they add. The analysts also cite Eli Lilly's market share gains in the U.S. and product differentiation, including greater weight loss and better tolerability. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
March 27, 2025 09:45 ET (13:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。